Results 201 to 210 of about 325,832 (305)

ADAM17 and its proteolytic targets in disease pathogenesis

open access: yesThe FEBS Journal, EarlyView.
ADAM17 as a multifunctional sheddase with contrasting roles across inflammatory, metabolic, cardiovascular, and neoplastic diseases. Through regulated activation by iRhom, iTAP/FRMD8, and tetraspanins, ADAM17 cleaves diverse membrane ligands and receptors, thereby promoting inflammation, fibrosis, obesity, insulin resistance, and tumor progression ...
Abdulbasit Amin, Marina Badenes
wiley   +1 more source

Exercise‐induced vasculitis with histological and genetic evidence of complement involvement

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Massimo Cugno   +6 more
wiley   +1 more source

Delphi Consensus Recommendations for the Definition of a Severe Bleeding Phenotype and Initiation of Prophylaxis in Patients With Non‐Severe Haemophilia

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Current guidelines recommend prophylaxis for patients with non‐severe haemophilia with severe bleeding phenotype (SBPT) but there is no consensus how to define a SBPT and when to recommend prophylaxis in patients with non‐severe haemophilia. Method A Delphi consensus procedure among the members of the Standing Committee Hemophilia
Christian Pfrepper   +10 more
wiley   +1 more source

Reversible cerebral vasoconstriction syndrome: A narrative review

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa   +7 more
wiley   +1 more source

Infected Aneurysm

open access: yesAnnals of Vascular Diseases, 2010
Kamphol, Laohapensang   +2 more
openaire   +3 more sources

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Home - About - Disclaimer - Privacy